Trials / Recruiting
RecruitingNCT05059951
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,000 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Detailed description
This prospective study aimed to assess its efficacy and adverse event for Checkpoint Inhibitors with or without chemotherapy in clincial practice. Several cohorts were devided including pathological type, treatment line, treatment regiems, combination strategies. Tissue samples were collected with permission of patients for TME evaluation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immune checkpoint inhibitor | Chemotherapy follow the guild line. |
Timeline
- Start date
- 2021-10-03
- Primary completion
- 2026-09-15
- Completion
- 2028-03-01
- First posted
- 2021-09-28
- Last updated
- 2024-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05059951. Inclusion in this directory is not an endorsement.